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ABSTRACT 
 
Clinical inertia (CI) is the failure to intensify treatment in patients with evidence 
of poor glycemic control. It is a critical barrier in the effective management of type 2 
diabetes and can have adverse effects, such as elevated risk of diabetes-related 
complications. The aims of this thesis are to study the long-term effects of CI and its 
interaction with population characteristics on the incidence of diabetes-related 
complications. An agent-based simulation has been constructed to study these effects. The 
base model was developed by researchers from The New York Academy of Medicine and 
the Icahn School of Medicine at Mount Sinai. It was then extended by adding an HbA1c 
update formula and treatment intensification processes, which offers a flexible avenue 
through which to compare diverse populations and parameters in a controlled and 
systematic approach. 
 To assess the accuracy of our model, we have conducted model validation using 
5 published trials and compared the rates of complication incidence. We performed 12 
validation exercises, comparing simulated outcomes with published outcomes. The R-
square of the overall fit was 0.9065, indicating overall good agreement between the 
outcomes. Thus, we concluded that the model was reliable for modeling the progression 
of diabetes-related complications in a population.  
Additionally, we performed a series of experiments to meet our aims. The results 
indicated that a 1-year, 3-year, and 7-year CI significantly increases the 25-year 
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cumulative incidence of most diabetes complications when compared to the non-CI group. 
It also indicates that CI has greater impact on specific race and age-group populations; for 
example, the 65-100 age-group experienced a significantly higher percent increase in the 
incidence of myocardial infarction, stroke, and retinopathy in comparison to the 45-64 
age-group while experiencing a 3-year CI. Additionally, it indicates that the incidence of 
neuropathy and nephropathy due to a 3-year CI in a Native American population is 
significantly less than the non-Hispanic White, African American, Hispanic, and Asian 
populations undergoing a 3-year CI.  Our model results provide insightful information for 
the development of effective diabetes treatment guidelines. Future research is needed to 
investigate the mechanism behind the differences among different population groups.   
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CHAPTER I  
INTRODUCTION  
 
The first chapter of this thesis provides background information concerning 
diabetes, diabetes-related complications, and treatment. In the last two sections of this 
chapter, the motivation, goal, and methodology selected for this thesis are discussed.  
I.1 Diabetes, Complications, and Treatment  
I.1.1 Diabetes Mellitus (DM)   
Diabetes mellitus is a complex, chronic disease where the body fails to produce or 
respond to the hormone insulin, which results in elevated blood glucose levels.  Diabetes 
mellitus can be classified into the following three major categories: type 1 diabetes, type 
2 diabetes, and gestational diabetes.  
Type 1 diabetes, also known as insulin-dependent diabetes, develops when the 
body fails to create the hormone insulin to regulate blood glucose. Type 1 diabetes patients 
must receive insulin by injection or pump to regulate their glucose. Type 1 diabetes 
mellitus is most common among children and young adults; hence it is often referred to as 
juvenile diabetes. According to the Center of Disease Control (CDC), the risk factors for 
type 1 diabetes may be autoimmune, genetic or environmental, but it remains uncertain.33 
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Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes mellitus 
(NIDDM), occurs when the body cannot create enough insulin to control blood glucose 
levels or when the body fails to respond appropriately to the insulin produced. This type 
of diabetes is associated with body weight, history of gestational diabetes, family history, 
age, sex, lifestyle, and race/ethnicity. Type 2 diabetes is common among adults above the 
age of 20, and makes up approximately 90% of all the diabetes cases. 33 
Unlike type 1 and type 2 diabetes, gestational diabetes mellitus (GDM) is usually 
a temporary illness. GDM is developed during pregnancy and is a result of pregnancy 
hormones. GDM is common among women with a family history of diabetes and obese 
women. The CDC reports that 5 - 10 % of women diagnosed with GDM will have diabetes 
after pregnancy, most commonly type 2 diabetes. 33 
In this thesis, we will focus on type 2 diabetes, due to its high prevalence 
worldwide. The objective of diabetes care and management is to reach and maintain a 
glycemic target assigned to each individual by their physician. For the typical non-
pregnant individual with type 2 diabetes, the glycemic target is commonly set to a glycated 
hemoglobin (HbA1c) of less than 7% (53 mmol/mol).46 The HbA1c is a measure of the 
mean blood glucose levels for the previous 2 to 3 months. People with type 2 diabetes use 
insulin, medications, and lifestyle modifications, such as improved diet and exercise, to 
meet their glycemic target. Failure to meet the glycemic goal can increase the person’s 
risk of complications such as cardiovascular disease, retinopathy, neuropathy, 
nephropathy, and, in severe cases, death. It has been reported that an increase of 1% in 
HbA1c is associated with an increased risk of 18%, 12 -14%, and 37% in cardiovascular 
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events, death, retinopathy or renal failure, respectively.17 Due to the elevated risk for 
complications, effective management of HbA1c levels is crucial.   
Diabetes is a progressive epidemic throughout the world, especially within the 
United States. In 2012, 29.1 million Americans, or 9.3% of the United States population 
had diabetes and approximately 1.4 million more individuals are diagnosed with diabetes 
each year.6 According to the American Diabetes Association (ADA), if present trends 
continue, by 2050 one in every three Americans will have diabetes. In the state of Texas, 
diabetes is the 6th leading cause of death with approximately 10.6% of the population 
impacted directly by the disease.13, 14 For this reason, we are particularly interested in 
observing the progression of diabetes in the state of Texas, especially in Bexar County, 
which has a higher prevalence rate of diabetes than Texas at 14.2% and whose 4th leading 
cause of death is diabetes. 13, 14 Our experiments, later described in Chapter IV, will use 
data from different sources to simulate the Bexar County population. 
I.1.2 Diabetic Complications   
I.1.2.1 Neuropathy   
Neuropathy is the medical term used to refer to general diseases of the nerves, 
which can be damaged from injury or sickness. Diabetes is the chronic disease most 
closely associated with neuropathy. There are three subdomains of neuropathy, the most 
common being peripheral neuropathy, which usually affects the feet and legs. Peripheral 
neuropathy in people with diabetes is commonly caused by poor glycemic control (HbA1c 
levels > 7%). It has been reported that up to 7.5% of type 2 diabetes patients had clinical 
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neuropathy at the time of diagnosis.40 The symptoms of peripheral neuropathy include 
tingling, numbness, burning and pain. Due to the nerves being damaged, they cannot carry 
messages to the brain concerning cuts or sores on the feet. Consequently, it is important 
for people with diabetes to regularly check their feet for ulcers and cuts because unhealed 
cuts and ulcers can often lead to other complications including lower-extremity 
amputations (LEAs). LEAs are rare, but are extreme complications among people with 
diabetes.  According to the World Health Organization (WHO), LEAs are 10 times more 
likely to occur in people with diabetes compared to people without diabetes.24 According 
to the CDC, there are approximately 80,000 LEAs performed among people with diabetes 
every year.7 In addition, there is a high mortality rate associated with this debilitating 
complication. The mortality rate for 1-year post amputation can be anywhere between 
10% and 50%, and for 5-year post amputation between 30% and 80%.24 
I.1.2.2 Retinopathy  
Diabetic retinopathy (DR) is a disease of the retina caused by diabetes, in which 
the small blood vessels of the retina are damaged.  DR is the leading cause of blindness in 
adults with diabetes. A person's risk for DR is associated with diabetes duration, poor 
glycemic control, race, smoking habits, blood pressure, and cholesterol levels. DR can be 
prevented by maintaining glycemic and cholesterol control, which is accomplished by 
receiving a comprehensive dilated exam at least once a year, and keeping a healthy 
lifestyle (exercise, no smoking, etc.). According to the Eye Disease Prevalence Research 
Group, in 2014 DR was estimated to have caused 195,000 cases of vision impairment and 
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blindness in the United States.5 DR is responsible for approximately 20% of new blindness 
among people ages 45 to 74 with type 2 diabetes.36 
I.1.2.3 Nephropathy  
Nephropathy refers to kidney disease or damage. Diabetic nephropathy is a type 
of nephropathy caused by diabetes mellitus, and it is the leading cause of end-stage renal 
disease (ESRD).19 It is estimated that approximately 40% of patients in the Unites States 
with ESRD have diabetes.1 Diabetic nephropathy consists of 4 different phases: micro-
albuminuria, macro-albuminuria, nephrotic syndrome, and chronic renal failure. There’s 
an elevated risk of diabetic nephropathy among people with diabetes that have high blood 
pressure, elevated HbA1c levels, and those of races with higher risks for nephropathy, 
such as African Americans.  It has been estimated that diabetes increases the risk of ESRD 
approximately 12-fold.4 The projections from a UKPDS model reported that 34.3% of 
type 2 diabetes patients are likely to have persistent microalbuminuria or worse by 20 
years of being diagnosed with diabetes and 38.3% by 25 years.1 However, achieving 
glycemic control has been proven to be effective in preventing the development of 
microalbuminuria and delaying the progression into further stages of nephropathy.20 
I.1.2.4 Cardiovascular Disease (CVD) 
Cardiovascular disease (CVD), which leads to myocardial infarctions (MI) and 
strokes, is the leading cause of death in people with diabetes. According to the American 
Heart Association (AHA) at least 68% of individuals 65 years or older with diabetes die 
from some type of heart disease and 16% die of stroke.42 In addition, the AHA also reports 
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that diabetic adults are 2 to 4 times more likely to die from heart disease than people 
without diabetes and people with diabetes also have a risk of mortality due to stroke that 
is almost 3-fold compared to non-diabetic people.42 A Finnish population-based study, 
found that people with type 2 diabetes without previous MI have approximately the same 
risk of having a MI as a person without diabetes that has had a previous MI.22 Other factors 
that increase the risk of CVD are age, hypertension, and obesity. One method for 
preventing cardiovascular events is maintaining controlled glucose levels.44 
I.1.2.5 Mortality 
 According to WHO more than 3 million people worldwide die from diabetes and 
diabetes-related complications every year.48 Due to the increased risk of developing 
diabetes-related complications, people with diabetes have a shorter life expectancy and 
higher all-cause mortality risk than non-diabetic individuals.39 
I.1.3 Treatment  
Type 2 diabetes is usually treated with combinations of medications and lifestyle 
modifications, all with the objective of reaching and maintaining glycemic control.  Due 
to the increasing amount of anti-hyperglycemic drugs and the uncertainty on the best 
treatment algorithm, many of the national and international organizations founded to 
prevent diabetes have developed their own recommendations for the management and care 
of type 2 diabetes The treatment guideline developed by The American Diabetes 
Association (ADA) was published in their Standards of Medical Care in Diabetes.46 We 
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used the ADA treatment algorithm when creating our model, adopting their algorithm for 
the modeling of the medical treatment process for simulated diabetic individuals.  
The ADA suggests that most people newly diagnosed with type 2 diabetes should 
begin with lifestyle modifications, which may include daily exercise and a healthy diet. If 
the lifestyle intervention alone does not maintain the glucose levels within the glycemic 
goal, then the patient should initiate metformin monotherapy. If the patient is intolerant to 
metformin, ADA suggests starting with another anti-hyperglycemic drug. If the HbA1c 
target is not reached using metformin monotherapy within 3 months of therapy initiation, 
it is suggested that the patient shift to dual therapy. Dual therapy consists of maintaining 
metformin treatment and adding a second drug from the following options: sulfonylurea, 
thiazolidinedione, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist, or basal 
insulin. The choice of the second-line drug is based on patient preferences with the goal 
of minimizing side effects, and reducing HbA1c levels. If the HbA1c goal is not met after 
3 months of dual therapy, it is recommended that the patient starts triple therapy, which 
consists of the addition of another oral anti-diabetic drug. If the HbA1c target is not 
reached after 3 months of triple therapy, then treatment should advance to combination 
injectable therapy.  
In the case of people newly diagnosed with diabetes with severely elevated glucose 
levels, the ADA recommends a different approach to the assignment of initial treatment. 
If the newly diagnosed diabetic has HbA1c levels greater than 9% and less than 10%, the 
ADA recommends dual therapy as the initial treatment. Similarly, if the diabetic has an 
HbA1c greater than 10% at diagnosis, the ADA recommends combination injectable 
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therapy as the initial treatment. A flowchart to the generally recommended ADA treatment 
algorithm is displayed in Figure 1.46  
 
 
 
 
 
Figure 1. Flowchart of ADA’s treatment algorithm for type 2 diabetes. 
 
 
 
I.1.3.1 Clinical Inertia 
Despite all the national and international evidence-based guidelines specifying the 
process of medication intensification, research suggests that only 33% of people with 
diabetes are achieving their glycemic target of an HbA1c less than 7% .43 Additionally, a 
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UK study on 80,000 patients with type 2 diabetes reported to have an average time to 
intensification of 3 years among patients with HbA1c levels greater than 7% .47 The delay 
in treatment intensification, despite the evidence of poor glycemic control, is called 
clinical inertia.  
Clinical inertia can be a result of many different factors, including provider factors, 
patient factors, and the health care system.35 In the provider-level, clinical inertia can occur 
due to a lack of knowledge and training, time constraints, or patient health concerns. For 
example, patients who are cared for by general practitioners were 2.95 times more likely 
to experience clinical inertia compared to patients treated by specialists. 35 The delay in 
treatment intensification can occur in the patient-level due to, for example, concerns about 
weight gain and/or hypoglycemia. Clinical inertia can also be an outcome of system-level 
factors such as poor access to health care services and expensive new medications.  
Many studies have revealed evidence of high prevalence of clinical inertia in the 
management of type 2 diabetes, and identified the factors associated with it.48, 35 Additional 
retrospective studies have identified some of the adverse short-term outcomes of clinical 
inertia, but there have been fewer studies regarding the long-term effects of clinical inertia 
on diabetes-related complications. The studies we found regarding the effects of clinical 
inertia on diabetes-related complications are described in detail in the literature review 
discussed in Chapter II.  
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I.2 Research Motivations and Goals   
As discussed in previous sections, diabetes mellitus is a complex, chronic disease 
that can lead to other severe complications. According to WHO, diabetes is the 6th leading 
cause of death in the world, having claimed a total of 1.59 million deaths worldwide in 
2015.49 In the United States, it has been projected that the number of Americans with 
diagnosed diabetes will increase by 165%, from 11 million in 2000 to 29 million in 2050.3 
There is an evident need to control the prevalence of this chronic disease, which can be 
enabled by the effective and timely control of glycemic levels; however, clinical inertia 
remains a critical barrier to effective care. According to epidemiological data, clinical 
inertia is responsible for an excess of at least 200,000 avoidable diabetes-related 
complications per year.48 Despite the various retrospective studies on clinical inertia, to 
our knowledge, no previous studies have examined the long-term effects clinical inertia 
has on diabetes-related complications. 
Thus, the primary purpose of this study is to determine the long-term impacts of 
clinical inertia on diabetes-related complications across different populations using an 
agent-based model. The model was programmed in AnyLogic, a Java-based multi-method 
simulation suite. The aims of this study are to use the agent-based model to test the impact 
of clinical inertia on the incidence of diabetes-related complications, including 
retinopathy, neuropathy, nephropathy, and CVD. Another aim of the study is to use the 
model to test the impact of interactions between clinical inertia and population 
characteristics, such as age, on the aggregate onset of diabetes-related complications.  
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I.3 The Choice of an Agent-Based Modeling Approach for This Research   
In the last few years, there has been an increase in the utilization of systems 
science methodologies such as system dynamics, discrete-event simulation, and agent-
based modeling to solve problems in the public health domain, such as the management 
of chronic diseases.30, 31 
To simulate the progression of diabetes and diabetes-related complications, we 
have selected agent-based modeling as our method. Although several simulation models 
of diabetes have been developed in other studies, many of them are Markov models, which 
do not consider population heterogeneity and past disease history. Moreover, Markov 
models have limitations in modeling adaptive behaviors, feedback loops, and contextual 
effects.31 To the best of our knowledge, agent-based modeling has only been used to study 
the progression of diabetic retinopathy in a population. Agent-based modeling can model 
more complex properties and simulate agents who can represent heterogeneous 
individuals and behaviors and, thus, represents a more advanced approach for population 
health modeling.32 
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CHAPTER II  
LITERATURE REVIEW   
 
II.1 Research on the Use of Agent-Based Modeling in Chronic Disease Management 
In 2013, Day et al. constructed an agent-based model of diabetic retinopathy 
(DR).11 The model was developed based on medical records of patients from the VA St. 
Louis Healthcare System Eye Clinic. The authors considered many patient 
characteristics—such as gender, age, and HbA1c—and determined which of these factors 
were associated to the progression of DR using logistic regression models. Within the 
agent-based model, the progression of DR was modeled using a state chart, which 
consisted of non-proliferative DR, proliferative DR, and blindness states. The medical 
records were separated into a developing and testing dataset, which allowed for model 
validation. The simulated DR patients showed no significant deviation from the cohort of 
real-world patients with regards to their progression of DR, and other predictors. The 
authors state that agent-based modeling is an emerging platform with unexplored potential 
for the management and study of chronic diseases. Moreover, in a later publication in 
2014, Day et al. used the same agent-based model to evaluate the effect of different 
screening intervals on the incidence of vision loss among a simulated cohort of patients.12 
The authors found that there was no significant difference between 1- and 2-year screening 
intervals and, thus, increasing the screening interval to 2 years was the most reasonable.  
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In 2014, Li et al. constructed an agent-based model of CVD to evaluate the effects 
of several lifestyle interventions—such as quitting smoking, improving diet, and weight 
loss—on the long-term prevalence and incidence of cardiovascular events across different 
populations.29 Each of the simulated individuals in the population was assigned several 
behaviors, which were chosen according to the American Heart Association’s (AHA) 
concept of ideal cardiovascular health. Data from the 2007 and 2012 Behavioral Risk 
Factor Surveillance System were used in the validation of the model. The authors showed 
that the effectiveness of an intervention varies from population to population and, thus, 
local health departments should consider population demographics when designing and 
implementing preventive interventions. 
In 2015, Zhang et al constructed an agent-based model to study the impact of social 
influence on the incidence of adolescent overweight and obesity, in an effort to improve 
existing interventions.52 The model was built using results from an R package, called 
SIENA (Simulation Investigation for Empirical Network Analysis), and the National 
Longitudinal Study of Adolescent Health. In order to ensure model accuracy, they 
performed model validation against empirical observations. Overall, they conducted five 
experiments in which characteristics of the high-BMI agents, agent interactions, strength 
of peer influence, BMI distribution, and dietary targets were varied. The results from the 
experiments suggested that an increased peer influence showed a substantial decrease in 
the prevalence of overweight; yet, the effect of peer influence varied by the distribution of 
BMI among the peers, where if the BMI was increased, strong peer include led to an 
increase in overweight prevalence.  
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II.2 Research on the Prevalence and Effects of Clinical Inertia  
In 2016 Osataphan et al. conducted a retrospective cohort study at a university-
based hospital in Thailand to assess the effects of clinical inertia, specifically the delay of 
insulin initiation, on the progression of DR within a non-insulin dependent diabetes 
mellitus (NIDDM) population.35 Ninety-eight patients were included in the study, all of 
which were already using at least 2 oral anti-diabetic drugs (OADs) as treatment and had 
an HbA1c level >9%. Approximately 68.7% of study participants were classified into the 
clinical inertia group. Clinical inertia was defined as failing to intensify treatment with 
insulin after 3 months of poor glycemic control. After a mean follow-up time of 29.5 
months, the median time of study enrollment to a new event of DR was significantly 
shorter within the clinical inertia group than the non-inertia group. The clinical inertia 
group had an incidence rate of 10 cases per 1000 person-months, while the non-inertia 
group had an incidence rate of 2.2 cases per 1000 person-months. The authors noted that 
a future study with a larger sample size and longer follow-up time would be beneficial to 
confirm the association between clinical inertia and diabetes related complications. 
In 2015 Paul et al. conducted a retrospective cohort study to evaluate the effect of 
clinical inertia on the risk of macro-vascular events within the first 2 years post diagnosis 
for type 2 diabetes patients.41 Based on a cohort of 105,477 patients, approximately 26% 
of the patients with poor glycemic control (HbA1c>7%) never received any treatment 
intensification during the 2 years post diagnosis. It was also found that all patients with 
poor glycemic control with a delay in intensification of 1 year had their risks of MI, stroke, 
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heart failure (HF), and composite macro-vascular events (CVE) increase by 67%, 51%, 
64%, and 62%, respectively, compared to patients with HbA1c <7% who received 
treatment intensification before 1 year from diagnosis. The authors also considered the 
history of CVD and found that among patients with HbA1c >7% and no history of CVD, 
a 1-year delay in intensification significantly increased their risk of MI, HF, stroke, and 
CVE by 80%, 63%, 50%, and 64%, respectively. The authors found that clinical inertia 
was associated with 42% and 48% increased risk of CVE among patients with and without 
a history of CVD, respectively.   
Based on the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes 
Model, Chen et al. constructed a discrete-event simulation model called Januvia Diabetes 
Economic (JADE) Model to study the impact of alternative HbA1c thresholds for 
treatment intensification.8 The authors studied the effect of varying the threshold for 
intensifying therapy from OADS to insulin and the threshold for intensifying insulin to 
multiple-dose insulin (MDL) treatment. The JADE Model was developed using Microsoft 
Visual Basic 6.3 with Microsoft Excel 2003, and it consisted of five modules: initial 
conditions of population, treatment, risk factor/adverse events, diabetes-related events, 
and costs. The model was used to make projections on the number of diabetes-related 
complications based on patient data from the Real-Life Effectiveness and Care Patterns of 
Diabetes Managements study. The seven diabetes-related complications recorded by the 
model were ischemic heart disease, MI, congestive heart failure (CHF), stroke, 
amputation, renal failure, blindness, and death. The model showed that lower HbA1c 
thresholds for the intensification of treatment resulted in a decrease in the projected 
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number of patients experiencing diabetes-related complications. Based on model 
projections with intensification thresholds for basal insulin and MDL at 7.0%, the patients 
spent approximately 54% of their time with HbA1c>7.0%. In comparison, if the threshold 
was 9.0%, then the patients spent 95% of their time with HbA1c >7%.  In addition, the 
model showed that clinical inertia could lead to a large increase in the incidence of MI; 
644 patients more than the baseline were projected to experience at least 1 MI within the 
first 5 years post diagnosis if the threshold was 9.0% compared to 7.0%. The projected 
incidence of amputation also showed a large increase resulting from higher thresholds.   
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CHAPTER III 
 MODEL STRUCTURE AND PARAMETERS   
 
 This chapter describes the model structure and parameters used in our agent-based 
model. Our model simulates the progression of diabetes and 4 diabetes-related 
complications: retinopathy, neuropathy, nephropathy, and CVD. This model includes 
some of the structures and parameters from published papers and other models, such as 
the CDC RTI Model.23  
III.1 Model User Interface 
 The agent-based model was constructed using AnyLogic University Researcher 
7.3.6, which is a Java-based simulation suite.16 This version of the software is accessible 
through the developer’s website and available for free download. AnyLogic allows for 
user interface design, and the interface of our model is shown in Figure 2. Using the 
interface, the user can input the characteristics of the population they want to simulate, 
specify the run length of the simulation, and initiate the simulation by clicking the ‘run’ 
button. 
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Figure 2. User interface of the agent-base model.  
 
 
 
III.2 Agent’s Characteristics 
Each agent’s characteristics, such as gender, race/ethnicity, height, weight, and 
age, are generated using the population characteristic, which can be input by users.   
III.2.1 Gender 
 One of the user inputs is the proportion of females in the population. The 
proportion is utilized as the probability, p, in a Bernoulli distribution, which determines 
the gender of each agent. The gender will take the value 1 with probability p, which means 
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the agent is female; otherwise, the gender takes the value of 0 with probability 1-p, which 
means the agent is male.  
III.2.2 Age 
 Each agent is assigned their age using the parameters inserted by the user. The 
parameters are used in a function programed into the model, which uses a normal 
distribution to return a value for each of the agents. The function ensures that the value 
falls within the minimum and maximum age values. This model was designed for the study 
of type 2 diabetes populations and, thus, it models only adult populations, which includes 
people 18 years and older. Additionally, a scheduled event within the model simulates the 
annual aging of each individual agent. When the event is triggered, a year is added to each 
of the agents’ age, unless the agent has already died.  
III.2.3 Race/Ethnicity 
 In real life, the risk of diabetes varies throughout ethnic groups; thus, the model 
was constructed to allow for the simulation of populations with various races/ethnicities. 
Race/ethnicity is assigned to each of the agents also using a function, which utilizes the 
user inputs as parameters. The races/ethnicities defined in our model include non-Hispanic 
White, African American, Asian, Hispanic, and Native American. Each of the 
races/ethnicities is represented by an integer for simplicity. The integers assigned are 1, 2, 
3, 4, and 5 to White, African American, Asian, Hispanic, and Native American, 
respectively.  
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 To simplify the model, we created a variable, RGL index that combines the gender 
and race of an agent to a single value. The RGL index is assigned whenever the simulation 
is initialized. The table describing the method of calculating each agent’s RGL index is in 
Appendix A. The RGL index remains constant once it is assigned to an agent in the 
beginning of the simulation. 
III.2.4 Height 
 The height of each agent is assigned using a function, which uses a normal 
distribution and the parameters (mean, standard deviation, minimum, and maximum) input 
by the user. An assumption of our model is that each of the agents has achieved their 
maximum height since they have reached adulthood; thus, the height for all agents remains 
a constant throughout the entirety of the simulation. Height in our model is specified in 
meters to simplify the calculation of the body mass index (BMI) of each agent. The method 
of calculating each agent’s BMI is described in later sections.  
III.2.5 Weight 
 The initial weight of each agent is determined using a function, which utilizes a 
normal distribution and the parameters (mean, standard deviation, minimum, and 
maximum) input by the user. Additionally, the weight in our model is assigned in 
kilograms (kg). Unlike the height parameter, the weight of an agent is continuously 
changing throughout the run of the simulation. Details on the process of an agent’s weight 
change is presented in Section III.4.1.   
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III.3 Agent’s Health Behaviors  
 Each agent has a set of state-charts that represent their health behaviors and health 
factors, which can develop simultaneously and interactively. During the run length of the 
simulation, agents may transition between states leading to status changes in their health.  
For our simulation, the transition between states happens at discrete-time intervals of 3 
months. Every 3 months, the model determines what fraction of the agents that will 
transition from one state to another based on transition probabilities. The transition 
probability pj,k (t) is the probability that an agent in state j at time t will move at time t+1 
to state k. The transition probabilities for all the state-charts are estimated from various 
published trials, and they can vary from agent to agent due to the transition probabilities 
being dependent on agent characteristics (gender, race, etc.) and the statuses of health 
behaviors and factors (smoking status, cholesterol, etc.). The health behaviors and factors 
state-charts are displayed in Figure 3.  
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Figure 3. State-charts of the health behaviors and factors. 
 
 
 
III.3.1 Smoking  
 The state-chart representing the current smoking status of the agent consists of two 
states, “Non Smoker” and “Smoker”. The proportion of currently non-smoking agents in 
the population is input by the user, which is then used by the model to determine the initial 
smoking status of each agent.  The proportion is utilized as probability p in a Bernoulli 
distribution. The smoking status will take the value 1 with probability p to represent a 
smoker; otherwise, the status will be 0, which represents a non-smoker. 
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 To determine the transition rates between the smoke states, the model uses the 
agent’s age and probability tables, SmokeStartProbTable and SmokeStopProbTable. The 
tables contain the probability of an agent, given their age, to start or quit smoking. The 
probability tables are shown in detail in the Appendix B.  
III.3.2 Physical Activity 
 The physical activity state-chart consists of two states, “Poor physical activity” 
and “Ideal Physical Activity”. The initial physical activity status is determined using a 
Bernoulli distribution and the proportion of physically active people in the population, 
which is specified by the user, as probability p. The agents with ideal physical activity 
have a physical activity status of 1, and those who have poor physical activity status have 
a value of 0. The transition rates between the states are shown in Table 1.  
 
 
 
 Poor to Ideal Ideal to Poor  Source 
Transition Rate 0.01225 0.01225  Dalziel et al.9 
 
Table 1. Physical activity state-chart transition rates.  
 
 
 
III.3.3 Diet 
 The diet state-chart consists of two states called “Poor Diet” and “Ideal Diet”. The 
initial value of the dietary status is determined using a Bernoulli distribution and the user 
inputs. The dietary status takes a value of 1 to represent an agent with ideal diet, and 0 for 
a poor diet. The transition rates are shown in Table 2.  
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 Poor to Ideal Ideal to Poor Source 
Transition Rate 0.00075 0.00075 Dalziel et al.10 
 
Table 2. Diet state-chart transition rates. 
 
 
 
III.4 Agent’s Health Factors      
 In addition to the health behaviors, the simulated agents also have state-charts 
representing health factors. The health factors modeled for each agent are body weight, 
cholesterol, and blood pressure.  
III.4.1 Body Weight  
 The body weight state-chart consists of three states, “Poor Weight”, “Very Poor 
Weight”, and “Ideal Weight”. Initially, the model calculates the BMI for each agent by 
dividing their weight by their height squared. The calculated BMI is then used to assign 
each agent into their corresponding weight state. If the BMI is less than 25, then the agent’s 
weight status is “Ideal Weight”. If the BMI is greater than 25 but less than 30, then the 
agent’s weight status is “Poor weight”; everything greater than 30 is considered “Very 
Poor Weight”. Agents at the “Ideal Weight” state have a weight status value of 1; 
otherwise, the weight status is equal to 0. The transition rates between each state are 
displayed in Table 3. 
Anytime in the simulation when an agent transitions into a new weight state, the 
agent is assigned a new BMI, which then is used to update their weight. The current weight 
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is updated by multiplying the height squared by the new BMI. The continuous change and 
update of weight is crucial to the HbA1c update formula described in section III.5. 
 
 
 
 
Table 3. Weight state-chart transitions. 
 
 
 
 The diet and activity status directly contribute to the transition rates between 
weight states; such that if an agent is currently in a poor weight state and has an ideal diet, 
where DietStatus is 1, and/or ideal activity status, where ActivityStatus is 1, the agent’s 
transition rate into a healthier weight is greater.  
III.4.2 Cholesterol 
The cholesterol state-chart consists of two states, “Poor Cholesterol” and “Ideal 
Cholesterol”. The parameters input by the user and a Bernoulli distribution determine the 
initial cholesterol status. The cholesterol status has value 1 whenever the agent has ideal 
cholesterol, and a value of 0 otherwise. The transition rates between the cholesterol states 
are determined using a probability table, HighCholesterolProbTable, which contains the 
probability of an agent having high cholesterol, and the agent’s weight status. The 
Transition Rate Source 
Poor to very poor 0.0025*0.76^DiestStatus*0.7^ActivityStatus 
Ogden et al.34, 
Kaukua et al.28, 
and Paul et al.41 
Poor to ideal 0.0025 * 2^DietStatus * 2^ActivityStatus 
Very poor to Poor 0.0025 * 2^DietStatus * 2^ActivityStatus 
Ideal to poor 0.0025*0.76^DiestStatus*0.7^ActivityStatus 
26 
 
transition rates are displayed in Table 4, and the probability table is displayed in the 
Appendix B.  
 
 
 
 Poor to Ideal Ideal to Poor Source 
Transition Rate 0.00025 
HighCholesterolProbTable(Age) * 
1.24^(1-WeightStatus) 
Panagiotakos et 
al.40 
 
Table 4. Cholesterol state-chart transition rates. 
 
 
 
III.4.3 Blood Pressure 
The blood pressure state-chart consists of two states, “Poor Blood Pressure” and 
“Ideal Blood Pressure”. The initial blood pressure status of an agent depends on the user 
inputs and a Bernoulli distribution, which returns a value of 1 for ideal blood pressure and 
0 otherwise. The transition rates between blood pressure states are shown in Table 5. The 
transition from ideal blood pressure to poor ideal pressure is a constant rate; however, the 
transition from ideal to poor blood pressure is interrelated with the agent’s weight status 
and their probability of hypertension. The probability table containing the probabilities of 
developing hypertension is displayed in Appendix B.  
 
 
 
 Poor to Ideal Ideal to Poor Source 
Transition Rate 0.00025 
Main.HypertensionProbTable(Age)* 
2.32^(1-WeightStatus) 
Vasan et al.50 
 
Table 5. Blood pressure state-chart transition rates. 
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III.4.4 Diabetes Status 
 Our model was constructed to allow for flexibility in assigning the agents’ initial 
diabetes status. There are two methods to assigning the initial diabetes status. The first 
method utilizes the HbA1c statistics specified by the user. The model then uses them in a 
normal distribution to determine each of the agent’s initial HbA1c. The initial HbA1c 
assignment method is designed so that it will not violate the minimum and maximum 
specifications. Once an agent is assigned an initial HbA1c, the model uses the HbA1c to 
determine the initial diabetes status of the agent. We assume in our model that the time 
from the onset of diabetes to diagnosis is set to 0 years. Thus, if the agent’s HbA1c is 
greater than 6.5%, the agent is then “diagnosed” as diabetic and becomes active in the 
“Have Diabetes” state in the blood glucose state-chart. An agent in the “Have Diabetes” 
state is assigned a diabetes status equal to 1.  Otherwise, the agent is considered non-
diabetic and it is given a diabetes status of 0. The blood glucose state-chart is displayed in 
Figure 4.  
The second method of determining the initial diabetes status of the agents is using 
the proportion of people without diabetes specified by the user. The model uses the 
proportion as the probability for a Bernoulli distribution to assign the initial diabetes status 
of each agent. Once the agents enter their designated state, they are assigned an initial 
HbA1c that is associated with their diabetes status. For agents that are active in the 
“Diabetes” state, they are assigned an initial HbA1c using a uniform distribution with 
minimum of 6.5% and a maximum of 12%. For the agents that are in the “Non-diabetes” 
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state, they are assigned initial HbA1c values using a uniform distribution with minimum 
of 4.0% and maximum of 6.4%.  
 The transition rates between the diabetes states depend on the current weight status 
of the agent and their diabetes probability table shown in Appendix B. Once the agent 
enters the Diabetes state, the agent cannot return back to the non-diabetes state.  
 
 
 
 
Figure 4. Blood glucose state-chart. 
 
 
 
III.5 Complication State-charts 
 In the simulation, each complication is modeled using a state-chart. The state-
charts are interrelated with the health behaviors and health factors state-charts. Initially, 
we assume that all agents have no history of any complication; thus, all agents begin the 
simulation at the normal state of each of the complication state-charts. Throughout the 
simulation run, the agent progresses simultaneously in the state-charts of these 
complications: cardiovascular disease, neuropathy, nephropathy, and retinopathy.  
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III.5.1 Cardiovascular Disease 
 The cardiovascular disease (CVD) state-chart, shown in Figure 5, consists of 
several states, which include MI, stroke, CVD-related death, and non-complication-related 
death. Each agent begins the simulation in the “No CVD” state, where we have 
programmed to determine each agent’s 3-month probabilities of having a MI or Stroke. 
The probabilities depend on gender, age, blood pressure status, smoking status, cholesterol 
status, and diabetes status. Once the probabilities are calculated, they are used as the 
transition probabilities into the CVD states. 
Due to the prevalence of fatal MI and stroke, the state-chart includes a decision 
point for each cardiovascular event, which determines whether the MI or stroke were fatal, 
based on a probability. The probability of a fatal stroke is determined using a condition 
which utilizes RandomTrue function, which generates True with a given probability p. 
The probability of a fatal MI is determined using the probability table DeathFirstMI, 
which contains the probability of an agent dying from their first MI. The probability table 
is shown in detail in Appendix B. If the MI or stroke were not fatal, the agents will 
transition into the MI or Stroke state, where they will remain until further transition. The 
transition rates between CVD states are shown in table 6.   
In addition, this state-chart also includes the transition to a death state, which 
includes all other non-complication related deaths. The transition into the death state 
depends on a probability table shown in detail in Appendix B.  
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Figure 5. Cardiovascular Disease state-chart. 
 
 
 
Transition Rate Source 
No CVD to MI 
ThreeMonthsProbMI * (pow(A1c/(7.0),3.07)) 
*pow(RGL,3.07) * 2 
 
No CVD to Stroke 
ThreeMonthsProbStroke * (pow(A1c/(7.0),3.07)) * 
pow(RGL,3.07)*2 
 
No CVD to MI Death randomTrue (Main.DeathFirstMI (Age) ) Hunink et al.25 
Stroke to Stroke Death randomTrue (0.0376)  
MI to MI death gender==0? Main.DeathMI1(Age):Main.DeathMI2(Age) Weinstein et al.51 
Stroke to Stroke Death 0.022875  
No CVD to Death 
gender==0? 
Main.DeathOther1(Age):Main.DeathOther2(Age) 
 
 
Table 6. Cardiovascular disease state-chart transition rates.   
 
 
 
III.5.2 Retinopathy  
 The retinopathy state-chart, shown in Figure 6, consists of three states, 
“RetiNormal”, “Photo”, and “Blindness”. At the start of the simulation run each agent 
begins at the “RetiNormal” state, which means agents have no history of retinopathy. The 
transition rate from the normal state to the first stage of retinopathy, photocoagulation, 
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depends on the blood pressure status, HbA1c, and RGL index. The transition rates to 
subsequent states are shown in Table 7. 
 
 
 
 
Figure 6. Retinopathy state-chart. 
 
 
 
Transition Rate Source 
RetiNormal to Photo 
(BPStatus==0?0.00275:0.00145)* 
pow(A1c/(A1c+A1cChange),2.74)*pow(RGL,2.74) 
Hoerger et al.23 
Photo to Blindness 0.026625 Hoerger et al.23 
 
Table 7. Retinopathy state-chart transition rates.  
 
III.5.3 Neuropathy  
 The neuropathy state-chart, shown in Figure 7, consists of several states, which 
include normal state, peripheral neuropathy, lower-extremity amputations (LEA), 
subsequent LEA, and LEA-related deaths. All agents begin in the “NeuroNormal” state, 
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which indicates no history of neuropathy. The transition from the normal state to the first 
stage of neuropathy, “PeriNeuro”, depends on the agent’s HbA1c and RGL index. The 
transition rates from the neuropathy state-chart are shown in Table 8.  
 
 
 
 
 
Figure 7. Neuropathy state-chart. 
 
 
 
 
Transition Rate Source 
NeuroNormal to 
PeriNeuro 
0.005625*(pow(A1c/(7.0),3.07))*pow(RGL,3.07) 
Hoerger et al.23 
PeriNeuro to LEA 0.00168 
LEA to SubLEA 0.0275 
LEA to LEADeath 0.02625 
SubLEA to LEADeath 0.02625 
 
Table 8. Neuropathy state-chart transition rates. 
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III.5.4 Nephropathy 
 The nephropathy state-chart has several states, which include normal state, micro-
albuminuria, clinical nephropathy (a.k.a. macro-albuminuria), ESRD, and ESRD-related 
deaths. The nephropathy state-chart is shown in Figure 8. Initially, all the agents are in the 
normal state, “NephNormal”, and their transition rates into the first stage of nephropathy, 
micro-albuminuria, depend on the agent’s HbA1c and RGL index. All the subsequent 
transition rates are displayed in Table 9. The transition rate between ESRD and ESRD 
death is different from the other rates. Once the agent enters the ESRD state, the model 
determines the agent’s probability of death due to their new nephropathy status. The 
probability of death is determined using the agent’s age, race and gender, and the 
probability is stored in the variable ProbESRDDeath.  
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Figure 8. Nephropathy state-chart. 
 
 
 
Transition Rate Source 
NephNormal to Micro 0.00505*(pow(A1c/(7.0),4.28))*pow(RGL,4.28) 
Adler et al.1, 
UKPDS 3821 
Micro to ClinicalNeph 0.0071 
ClinicalNeph to ESRD 0.0058175 
ESRD to ESRDDeath ProbESRDDeath Dong et al.15 
 
Table 9. Nephropathy state-chart transition rates. 
 
 
 
III.6 Glycemic Control and Treatment 
 Diabetes management is focused on the timely and effective management of 
glucose levels. Thus, it was crucial that our model effectively simulated the continuous 
changes in HbA1c levels and the progression of step-wise intensification of treatment for 
each agent with diabetes. According to ADA diabetes care guidelines, a diabetic individual 
35 
 
should have their HbA1c tested every 3 months, which then determines if the individual 
requires treatment intensification. To model this process, our model has an event that 
occurs every 3 months, which updates the HbA1c values and initiates the step-wise 
intensification, if necessary. The event updates the HbA1c of each of the agents using the 
following equation:  
A1ci = A1ci-1 + z + x - m  
, where the variables z, x, and m represent the changes in HbA1c associated with the 
change in age, weight change, and medication intensification, respectively. The z variable 
represents the rate of change for HbA1c that is associated with aging, and it is calculated 
using the annual rate of change shown in Table 10. In order to use it in our model, we 
transformed the annual rate to a 3-month rate.  
 
 
 
Annual Rate of Change for HbA1c Source 
0.2 Dong et al.15 
Table 10. Annual rate of change for HbA1c.  
 
 
 
The x variable represents the change in HbA1c associated with weight change, where 
the weight change is calculated each time the agent transitions between any of the weight 
states and the weight is updated. The change in weight used to determine the value of the 
x variable by multiplying the change in weight by a rate of change in HbA1c, which is 
shown in Table 11. In order for the HbA1c to only reflect the last 3 months, the x is set to 
0 after every HbA1c update event. 
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 Rate of Change in HbA1c (per kg) Source 
Weight Gain Normal (0.002, 0.2560) 
Kamil et al.27 
Weight Loss Normal (0.03, 0.8534) 
 
Table 11. Rate of change for HbA1c associated with weight change. Normal (Mean, 
Standard Deviation)  
 
 
 
Lastly, the m variable is associated with the change in HbA1c resulting from an 
intensification of treatment. During each HbA1c update event, a series of conditional 
statements are used to determine if an agent requires an intensification of treatment. 
Firstly, the agent must be alive to receive intensification of treatment. Secondly, the agent 
must have diabetes to receive any treatment. Thirdly, the agent must be in poor glycemic 
control. If the three conditions have been met, the agent can receive treatment 
intensification. 
 In order to track the agent’s current treatment method, a variable numTreatment 
is given values from 1 to 4, each representing the medication stages recommended by the 
ADA, which are monotherapy, dual therapy, triple therapy, and combination injectable 
therapy. During each treatment intensification, the variable numTreatment is increased to 
the next treatment method and the m variable is assigned a value following the distribution 
shown in Table 12. After each HbA1c update, the m variable is set to 0 to avoid 
duplication. A flowchart of the process of assigning values to the variables is displayed in 
Figure 9.  
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One-Time Initial Treatment Effect on HbA1c Source 
Uniform (1, 1.25) Sherifali et al.45 
 
Table 12:  One-time initial treatment effect on HbA1c. 
 
 
 
 
 
Figure 9. HbA1c update flowchart.  
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III.7 Agent’s Life Cycle 
In order to best describe the model, the following section describes two scenarios, 
non-clinical inertia and clinical inertia, which were used for the experiments specified in 
Chapter IV.  
 In the case of a typical agent, the agent is initially assigned all of their 
characteristics (age, weight, height, etc.), and statuses of their health factors (cholesterol, 
blood pressure, etc.) and health behavior state-charts (smoking, physical activity, etc.) 
according to the user inputs. The agent is also initially given the status of its complication 
status, which starts in the “normal state”. Figure 10 shows the flowchart for a typical agent 
in the non-clinical inertia scenario. Meanwhile, Figure 11 displays the flowchart for a 
typical agent in a 3-year clinical inertia scenario.  
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Figure 10. Non-clinical inertia flowchart.  
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Figure 11. Clinical inertia flowchart.  
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CHAPTER IV 
 VALIDATION  
 
IV.1. Model Validation  
 To assess the accuracy of our agent-based model, we conducted model validation 
using several published clinical trials and compared the rates of complication incidence 
between simulation results and trial outcomes. We performed 14 validation exercises 
comparing the simulated outcomes with the outcomes from 6 published trials. To simulate 
the outcomes of each of the clinical trials, we generated a population cohort with similar 
baseline characteristics, which were provided in each of the trials, and then modeled the 
development of diabetes-related complications for the same follow-up durations as in the 
trial.  
 Based on the structure of our model, we created the simulated population using the 
following variables: age, sex, ethnicity/race, BMI, HbA1c, smoking status, blood pressure, 
total cholesterol, physical activity, and diet. For each of the complication, we utilized 
published trials that had outcomes only for type 2 diabetes patients. The outcomes that 
were measured were regarding the following complications: retinopathy, cardiovascular 
disease, neuropathy, nephropathy, and mortality. We assessed the goodness-of-fit for the 
model by plotting the model results against the published trial results and then calculating 
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the R-squared value, which measures how much of the actual variance our model can 
explain.  
 The details in each study and the comparison between outcomes are shown in 
Table 13. The results show that for most of the complications, the simulated results closely 
match published results.  
 
 
 
Trial 
Treatment 
Group 
Duration Outcome 
Study 
Result 
Model 
Result 
UKPDS 
3326 
Newly 
diagnosed 
NIDDM people 
10yrs. 
Absolute risk of 
retinopathy events per 
1,000 pt-yrs 
11 5.95 
Absolute risk of MI 
events per 1,000 pt-yrs 
17.4 7.20 
Absolute risk of stroke 
events per 1,000 pt-yrs 
5.00 3.14 
ACCORD17 
Newly 
diagnosed 
NIDDM people 
ages 40 – 75 in 
UK or Ireland 
4yrs. 
Cumulative incidence of 
CVD death 
1.8% 1.1% 
Cumulative incidence of 
non-fatal MI 
4.6% 4.30% 
Cumulative incidence of 
non-fatal stroke 
1.20% 2.50% 
Partanen et. 
Al40 
Finnish newly 
diagnosed 
NIDDM people 
10yrs. 
Cumulative Incidence of 
neuropathy 
20.90% 16.50% 
 
Table 13. Summary comparison of published study results with results from the model.  
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Study 
Treatment 
Group 
Duration Outcome 
Study 
Result 
Model 
Result 
UKPDS 
641 
Newly 
diagnosed Type 
2 diabetics 
15 yrs. 
Cumulative incidence of 
micro-albuminuria or worse 
nephropathy 
28.0% 25.9% 
Cumulative incidence of 
macro-albuminuria or 
worse nephropathy 
7.1% 7.5% 
Cumulative incidence of 
ESRD or worse 
nephropathy 
2.3% 2.1% 
Li et. Al29. 
Control group 
of Chinese 
people w/ IGT 
6yrs 
All-cause mortality 
cumulative incidence 
3.7% 4.7% 
20yrs 29.3% 24.2% 
 
Table 13 (continued).  
 
 
 
To further evaluate the model’s accuracy, we compared the aggregate fit across 
complications by plotting the model results against clinical study results and estimating 
the correlation. The plot for the validation results is shown in Figure 12. The regression 
line slope of 0.7951 is close to 1.00, and the value of R-squared is 0.9065, which indicates 
that our model explains approximately 91% of the variance in the actual data. The model 
fits the data well because the results fall closely to the 45-degree line, which denotes 
perfect correlation between model and study results.  
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Figure 12. Comparison of the modeled diabetes-related complication incidence rates to 
the observed results from published trials.  
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CHAPTER V 
EXPERIMENTS AND OUTPUTS  
 
This chapter provides information on the designed experiments and the statistics 
collected on the model populations in effort to meet the aims specified in Chapter I.  
V.1 Description of Experiments and Model Outputs 
  To meet the aims of this thesis, we designed an experiment for each of the aims. 
The aims of this thesis are:  
Aim 1: Use the agent-based model to study the impact of clinical inertia on the incidence 
of diabetes-related complications.  
Aim 2a: Use the agent-based model to study the impact of interactions between clinical 
inertia and age on the aggregate onset of diabetes-related complications.   
Aim 2b: Use the agent-based model to study the impact of interactions between clinical 
inertia and race on the aggregate onset of diabetes-related complications.   
Aim 2c: Use the agent-based model to study the impact of interactions between clinical 
inertia and gender on the aggregate onset of diabetes-related complications.   
For all of the experiments described in the following paragraphs, the simulations 
had a run length of 25 years and were replicated 15 times each. Each of the replications 
consisted of a population of 10,000 simulated agents with diabetes, which were modeled 
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according to the population characteristics of Bexar County, Texas. The population 
characteristics are described in detail in Appendix C.   
V.1.1 Experiment 1: Impact of the Clinical Inertia on the Incidence of 
Complications 
 For the first aim of this project, we designed an experiment which used the 
incidence of complications as the response variables and the duration of clinical inertia as 
the factor. We created 4 simulations where each modeled different durations of clinical 
inertia, which were 3 months, 1 year, 3 years, and 7 years. The duration of clinical inertia 
represented the time that an agent remained in poor glycemic control before their first 
treatment intensification. The simulation with the 3-month clinical inertia was the non-
clinical inertia scenario based on the ADA guidelines which require patients to wait a 3-
month period after each treatment initiation and before the physicians can suggest 
treatment intensification. The non-clinical inertia scenario was used as the baseline group, 
which was used to compare to the other scenarios with longer clinical inertia durations. 
The purpose of this experiment was to make the comparisons and calculate the percent 
increase in the incidence of complications between the non-clinical inertia and clinical 
inertia groups. Additionally, the controls of this experiments were the population 
demographics and the remaining user inputs. The results from this experiment are 
displayed in Table 14. 
Additionally, we utilized Minitab Software to perform two-sample t-tests to 
compare the different scenarios. The two-sample t-test is designed to compare the means 
47 
 
of two populations while assuming the response variables were normally distributed and 
the data from both populations have equal variances. In the case of not normally 
distributed data, we used Mann-Whitney statistical tests, which uses the median to make 
the comparisons instead of the mean. For each of the clinical inertia groups, we compared 
their cumulative incidences to the ones from the baseline group. The two-sample t-tests 
showed that there was a statistically significant difference between the baseline and all 
clinical inertia groups, in which the clinical inertia scenarios had a higher cumulative 
incidence for all complications, except for fatal MI. The results from the Mann-Whitney 
tests are displayed in Appendix D.  It was also observed that as the clinical inertia duration 
increases so does the percent increase in incidence of complications. 
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V.1.2 Experiment 2: Impact of the Interaction between Clinical Inertia and 
Population Characteristics on the Incidence of Complications 
For the second aim, we constructed three individual experiments to study the 
impact of the interaction between clinical inertia and several population characteristics, 
which were age, gender, and ethnicity/race, on the incidence of diabetes-related 
complications. In each of the three experiments, the response variables were the incidence 
of complications, and the controls were the population demographics and the remaining 
user inputs. Each experiment had different factors: age, gender, and ethnicity, where each 
factor had subcategories.  In each experiment, two populations were simulated for each 
subcategory. The first modeled the baseline non-clinical inertia group, which received 
treatment intensification as necessary and as recommended by the ADA. The second 
modeled the clinical inertia group which experienced a 3-year delay in treatment 
intensification. All of the populations were modeled to be 100 % diabetic, because we are 
only interested in the effect of clinical inertia on the health of people with diabetes.  
V.1.2.1 Experiment 2a: Impact of the Interaction between Clinical Inertia and Age 
on the Incidence of Complications 
 For this experiment, we utilized the National Health and Nutrition Examination 
Survey as a guide to determine an appropriate way to divide agents into age-groups. The 
age-groups were determined as 20 to 44, 45 to 64, and 65 to 100.  
In an effort to understand the implications of the model results, we performed a 
series of statistical tests, which consisted of 2-sample t-tests and one-way ANOVA tests. 
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Similarly to experiment 1, we used Minitab software to run these tests. Initially, to confirm 
that the clinical inertia group resulted in higher incidence of complication, we used 2-
sample t-tests to compare the mean incidences between the baseline and the clinical inertia 
scenario of each age group. The results in Table 15 show that the clinical inertia scenario 
did have significantly higher incidences on all complications than the non-clinical inertia 
group. 
Secondly, we used one-way ANOVA tests to compare each of the clinical inertia 
group’s mean percent increase in complication incidence in effort to study the different 
effect of clinical inertia between age-groups. For each of the complications, we compared 
three percent increases of incidences, where each corresponded to an age-group. Several 
ANOVA results suggested one of the means was different, and thus, we also performed 2 
sample t-tests between all means, trying all combinations, to understand which means 
were significantly different. The results are shown in Table 16.  
The model seems to suggest that the 65-100 age group is affected by clinical inertia 
significantly more than the 45-64 age group in the incidences of MI, stroke, and 
retinopathy by 21.6%, 21.8%, and 27.8%, respectively. The 65-100 age group also is 
affected by clinical inertia significantly more than the 20-44 age group in the incidences 
of retinopathy, nephropathy, and complication-related deaths by 21.8%, 27.1%, 6.1%, and 
16.4%, respectively. According to the model results, it might be of interest for public 
health officials to investigate the effects of clinical inertia on elderly populations in the 
future to validate the results from our models.  
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V.1.2.2 Experiment 2b: Impact of the Interaction between Clinical Inertia and 
Ethnicity/Race on the Incidence of Complications 
In this experiment, we studied the following ethnicities/races: Non-Hispanic 
White, African American, Hispanic, Native American, and Asian. We performed two-
sample t-tests to understand the effect of clinical inertia compared to non-clinical inertia 
group, and then performed the ANOVA test to understand the differences in the effect of 
clinical inertia between ethnicities/races. 
 The results for the two-sample t-tests are shown in Table 17. The results from the 
ANOVA tests are shown in Table 18. According to our model, the non-Hispanic White 
group is affected by clinical inertia significantly more than the African American 
population in the incidence of neuropathy, and nephropathy by 2.7% and 3.0%, 
respectively. The model also shows that the Native American group is affected by clinical 
inertia significantly less than the non-Hispanic White, African Americans, Hispanic and 
Asian population groups in the incidence of neuropathy by 5.4%, 2.7%, 3.8%, and 4.2%, 
respectively; similarly, it is significantly less in the incidence of nephropathy by 11.0%, 
8.0%, 7.9%, and 13.9%, respectively. The Asian group was impacted by the 3-year clinical 
inertia significantly more than the African American, Hispanic, non-Hispanic White, and 
Native American groups in the incidence of nephropathy by 5.9%, 5.9%, 2.9%, and 
13.9%. The non-Hispanic White was affected by the clinical inertia significantly more 
than the Hispanic, and Native American population in the incidence of complication-
related deaths by 6.5%, and 5.8%, respectively.   
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V.1.2.3 Experiment 2c: Impact of the Interaction between Clinical Inertia and 
Gender on the Incidence of Complications 
In this experiment, the two subcategories were female and male. Similar to the 
previous experiments, we performed 2 sample t-tests to understand the effect of clinical 
inertia compared to non-clinical inertia group, and then performed ANOVA test to 
understand the differences in the effect of clinical inertia between males and females. The 
results for the comparison of the non-clinical inertia group and the clinical inertia group 
are shown in Table 19.  
The results show that clinical inertia does result in higher incidence rates for all 
complications in both gender populations. The results from the ANOVA tests are shown 
in Table 20. The model results suggest that clinical inertia does not affect females and 
males differently. 
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  CHAPTER VI 
DISCUSSION AND CONCLUSION  
 
This chapter provides a summary of the development of our agent-based model, 
and the results obtained from the experiments. Lastly, potential areas of future work are 
presented.  
VI.1 Discussion 
Clinical inertia is a critical barrier to the effective treatment of diabetes mellitus. 
Despite its prevalence, there have been few studies on its effects. A clear understanding 
of the effects clinical inertia has on diabetes and diabetes-related complications is critical. 
Computer modeling is increasingly being recognized as a practical approach to study 
different chronic diseases, such as diabetes, and various treatment methods.30, 31 This study 
sets out to assess the impact of clinical inertia using a flexible, agent-based simulation 
model. In our study, we found that clinical inertia increases the incidence of diabetes-
related complications among type 2 diabetes agents. These results are broadly consistent 
with the existing literature, such as the reported outcomes by Osataphan et al. and Paul et 
al., which state that clinical inertia increases the risk of diabetes complications.31, 37 
Additionally, the study demonstrated that clinical inertia increases the incidence 
of diabetes-related complications significantly more on certain age and ethnicity groups. 
This is the first study, to our knowledge, that examines the effect of the interaction between 
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clinical inertia and population characteristics on the incidence of diabetes-related 
complications.  
Our study has some limitations. First, our model only predicts the first event of 
diabetes complications, similar to the CDC RTI model, on which our model is partially 
based on.  Consequently, we are only able to track the cumulative incidence of only the 
first event of diabetes complications. Secondly, our model’s treatment intensification 
algorithm is based solely on the agent’s glycemic levels, whereas in reality a treatment 
intensification may be based on other risk factors, such as agent age or overall health. 
Third, the treatment intensification algorithm does not include the discontinuation of 
medication, which in reality can happen due to medication side effects. Fourth, our model 
assumes that the patients are fully adhered to their medication instructions.  Fifth, the 
agents in our model are not in additional treatments or interventions, whereas in reality, 
they might be in multiple treatments and/or interventions for other health conditions. 
Sixth, our model assumes that the time from the onset of diabetes to diagnosis is set to 0 
years, whereas in reality the patient may go undiagnosed for a few weeks or months. 
Finally, the modeling of clinical inertia assumes that it is a one-time occurrence, where 
the patient resumes timely treatment intensification after their first episode of clinical 
inertia. This assumption was made due to lack of literature on the frequency of clinical 
inertia.   
Although it has several limitations, our model was validated using previously 
published clinical trials. Additionally, even though the experiments were conducted on 
Bexar County population, the validation of our model supports the accuracy of the agent-
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based model for other populations. Our study’s findings can contribute considerably to the 
development and evaluation of treatment guidelines for type 2 diabetes patients. More 
research in this area is necessary, particularly with real patient data.  
VI.2 Summary of Thesis Research 
 In conclusion, this thesis provides a simulation tool to evaluate the effects of 
clinical inertia on long-term outcomes of type 2 diabetes patients. The results of this study 
broaden the knowledge on clinical inertia on long-term outcomes. Our study suggests that 
clinical inertia leads to higher incidence rates of diabetes-related complications, and that 
clinical inertia does not affect genders differently, but it does increase the incidence rate 
of complication for particular age and ethnic groups. These findings may help health 
providers and policymakers better understand the potential adverse impact of clinical 
inertia on diabetes outcomes across different populations. 
 VI.3 Contribution   
The thesis research made two important contributions to the knowledge of clinical 
inertia research and chronic disease modeling. 
Previous research has sought to understand the prevalence and causes of clinical 
inertia on the treatment of type 2 diabetes. Our thesis offers a deeper understanding of 
clinical inertia by studying its long-term effects and the effects of its interaction with 
different population characteristics on the incidence of diabetes-related complications. 
Our study reported that clinical inertia increases the incidence of complications in the 
long-term, and that it affects some ethnic and age groups on a higher scale than others. To 
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the best of our knowledge, there are no other studies on the effects of clinical inertia on 
age-groups, ethnic groups, nor gender. Thus, the implications of our model results provide 
valuable and insightful information for the development of effective diabetes treatment 
guidelines, in particular, for the population groups that are suggested to be most affected 
by the delay of treatment intensification.  
Our thesis research also made contributions through the development of the agent-
base model, which was specifically modified to study clinical inertia.  To the best of our 
knowledge, agent-based modeling has only been used to study the progression of diabetic 
retinopathy in a population. Our model can offer more flexibility, by providing projections 
of the incidence of 5 different diabetes-related complications and the prevalence of 
diabetes in a broader range of simulated populations. A large portion of the previous 
modeling work on diabetes has been through Markov models, which offer less intuitive 
user interfaces. Our model is built with Anylogic, which allows for intuitive animated 
presentations for users to understand the system in a more effortless way.  
Most importantly, the current model has the capacity for straightforward integration of 
other diabetes interventions. While the integration of other diabetes interventions is out of 
the scope of this thesis, it is among one of the avenues for future work discussed in the 
next section. 
VI.4 Future Work   
 A few areas with potential for improvement have been identified, but fall outside 
the scope of this thesis due to time limitations and other considerations. First, additional 
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investigation using the agent-based model should be performed. For example, an 
investigation on the impact of clinical inertia on the time to onset of diabetes-related 
complications and death. Secondly, further research should be conducted with regards to 
the interaction of clinical inertia and population characteristics, particularly age and 
ethnicity/race. Lastly, further improvements should be made to the agent-based model to 
include additional interventions (diet, physical activity, medication, etc.), all in an effort 
to help evaluate or create treatment algorithms for type 2 diabetes patients.   
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APPENDIX A 
 
Calculating RGL Index 
 
if (Race==1 && gender==0) 
{RGL=1;} 
else if (Race==1 && gender==1) 
{RGL=1;} 
else if (Race==2 && gender==0) 
{RGL=1.04;} 
else if (Race==2 && gender==1) 
{RGL=1.09;} 
else if (Race==3 && gender==0) 
{RGL=1.09;} 
else if (Race==3 && gender==1) 
{RGL=1.04;} 
else if (Race==4 && gender==0) 
{RGL=1.19;} 
else if (Race==4 && gender==1) 
{RGL=1.19;} 
else if (Race==5 && gender==0) 
{RGL=0.95;} 
else 
{RGL=0.95;} 
 
 
Figure A-1. Series of if statements to determine RGL index for each agent, where 1 is 
female and 0 is male, and 1,2,3,4,5 correspond to non-Hispanic White, African American, 
Hispanic, Native American, and Asian, respectively.  
  
75 
 
APPENDIX B 
 
Smoking Initiation and Cessation Probability Tables. 
Table B-1 and Table B-2 contain the age-specific smoke initiation and cessation 
probabilities, respectively.18 
Age Probability of Starting to Smoke 
9.0 0.001255503 
11.0 0.002522152 
13.0 0.005089752 
15.0 0.010368573 
17.0 0.018676257 
19.0 0.018676257 
21.0 0.009030316 
23.0 0.005089752 
25.0 0.002522152 
27.0 0.002522152 
29.0 0.001887421 
31.0 0.001255503 
33.0 6.26372E-4 
 
Table B-1. The age-specific probabilities of smoking initiation. 
 
Table B-2. The age-specific probabilities of smoking cessation. 
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High Cholesterol Probability Table 
 
Table B-3 shows the age-specific probabilities of an agent having high 
cholesterol.37 
Table B-3. The age-specific probabilities of having high cholesterol. 
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Blood Pressure Probability Table 
Table B-4 shows the age-specific probabilities of an agent having hypertension.50 
 
Age Probability of Hypertension 
50.0 0.0 
55.0 0.002156969 
65.0 0.003695434 
 
Table B-4. The age-specific probabilities of having hypertension. 
 
 
Diabetes Probability Table 
Table B-5 shows the age-specific probabilities of an agent having diabetes. 
 
Table B-5. The age-specific probabilities of having diabetes. 
 
 
 
Death from First MI Probability Table 
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Table B-6 shows the age-specific probabilities of having a fatal MI.  
 
 
 
Age Probability of Death from 
First MI 
0.0 0.0 
15.0 0.003872436 
44.0 0.003872436 
45.0 0.008507964 
54.0 0.008507964 
55.0 0.018771998 
64.0 0.018771998 
65.0 0.042281841 
74.0 0.042281841 
75.0 0.083777257 
99.0 0.083777257 
100.0 1.0 
 
Table B-6. The probability of death from first MI, specified by age. 
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Death after First MI 
Table B-7 and Table B-8 shows the age-specific probabilities of dying after first 
MI for females and males, respectively.  
 
 
 
Age Probability of Death After 
First MI 
0.0 0.0 
15.0 0.001151989 
44.0 0.001151989 
45.0 0.002685801 
54.0 0.002685801 
55.0 0.004632085 
64.0 0.004632085 
65.0 0.008277202 
74.0 0.008277202 
75.0 0.027596477 
99.0 0.027596477 
100.0 1.0 
 
Table B-7. The age-specific probabilities of dying after first MI for females. 
 
 
 
Table B-8. The age-specific probabilities of dying after first MI for males. 
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All-cause Mortality Probability Table 
Table B-9 and Table B-10 shows the age-specific probabilities of all-cause 
mortality for females and males, respectively. 
 
 
Table B-9. The age-specific probability of all-cause mortality for females. 
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Table B-10. The age-specific probability of all-cause mortality for males.  
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APPENDIX C 
 
Bexar County Population Data 
Total Population 10,000    
Age 34.98 
(mean) 
22.17 
(standard deviation) 
20 
(Min.) 
100 
(Max.) 
Height 1.52 
(mean) 
0.50 
(standard deviation) 
1.67 
(Min.) 
1.87 
(Max.) 
Weight 80 
(mean) 
14 
(standard deviation) 
62 
(Min.) 
140 
(Max.) 
Female 50.4%    
Race White 30%   
 African American 7%   
 Hispanic 58.9%   
 Native American 1.5%   
 Asian 2.6%   
HbA1c 7.02 
(mean) 
1.72 
(standard deviation) 
3.3 
(Min.) 
19.9 
(Max.) 
No Diabetes 91%    
No Smoking 84%    
Physically 
Active 
78%    
Diet 22%    
No History of 
Hypertension 
    
No History of 
High Cholesterol 
    
 
Table C-1. The Bexar County 2013 data used to run experiments. This data was obtained 
through County Health Rankings and the Texas Demographic Center. The weight and 
height parameters were estimated using BMI data, and diet percent was estimated using 
access to healthy food in Bexar County. No data was available for the history of 
hypertension or high cholesterol.  
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